Dec 12, 2017 7:00am EST Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
Nov 7, 2017 7:00am EST Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
Nov 1, 2017 7:00am EDT Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
Oct 17, 2017 7:00am EDT Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
Oct 12, 2017 7:00am EDT Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
Sep 29, 2017 7:00am EDT Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
Sep 14, 2017 4:05pm EDT Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Sep 6, 2017 7:00am EDT Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
